805250-17-3

Basic information

• Product Name: 3-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester
• Synonyms: 3-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester;SR03298A;Methyl 2-(5-hydroxy-2,3-dihydro-1-benzofuran-3-yl)acetate;METHYL 2-(6-HYDROXY-2,3-DIHYDROBENZOFURAN-3-YL)ACETATE;-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester;(6-Hydroxy-2,3-dihydrobenzofuran-3-yl)acetic acid methyl ester;Methyl (6-hydroxy-2,3-dihydro-1-benzofuran-3-yl)acetate;Methyl 6-Hydroxy-2,3-dihydrobenzofuran-3-ylacetate
• CAS NO: 805250-17-3
• Molecular Formula: C₁₁H₁₂O₄
• Molecular Weight: 208.21058
• Mol File: 805250-17-3.mol

Chemical Properties

• Boiling Point: 326.5±42.0℃ (760 Torr)
• Flash Point: 126.9±21.4℃
• Appearance: /
• Density: 1.257±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.77±0.40(Predicted)
• CAS DataBase Reference: 3-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester(805250-17-3)
• EPA Substance Registry System: 3-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester(805250-17-3)

Safety Data

• Hazardous Substances Data: 805250-17-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Benzofuranacetic acid, 2,3-dihydro-6-hydroxy-, Methyl ester is used as a synthetic intermediate for the development of novel oral medications, specifically for TAK-875 (T004915). 3-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester plays a crucial role in the synthesis of a medication designed to enhance insulin secretion in a glucose-dependent manner, which can potentially improve blood sugar control without the risk of hypoglycemia. This application is particularly relevant for the management of diabetes and related metabolic disorders, offering a promising avenue for the development of safer and more effective treatments.

Upstream product

• 67-56-1 methanol 
• 1000414-37-8 2-(6-hydroxy-2,3-dihydrobenzofuran-3-yl)acetic acid 
• 69716-04-7 2-(6-hydroxy-1-benzofuran-3-yl)acetic acid 
• 108-46-3 recorcinol 
• 25392-41-0 4-chloromethyl-7-hydroxycoumarin 
• 726174-52-3 (6-hydroxy-benzofuran-3-yl)-acetic acid methyl ester 
• 93772-88-4 6-methoxy-3-methoxycarbonylmethyl-2,3-dihydrobenzofuran 

Downstream Products

• 1356599-30-8 {6-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]-2,3-dihydro-benzofuran-3-yl}acetic acid 
• 1356600-64-0 methyl {6-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]-2,3-dihydro-benzofuran-3-yl}acetate 
• 805248-74-2 methyl 2-[6-((2',4'-dimethylbiphenyl-3-yl)methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetate 
• 805248-75-3 2-[6-[(2',4'-dimethylbiphenyl-3-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid 
• 805248-71-9 {6-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl}acetic acid 

Relevant articles and documents

Compound with glucose-reducing and lipid-regulating effects as well as preparation and application thereof

The invention discloses a compound with glucose-reducing and lipid-regulating effects as well as a preparation and application thereof. The compound with glucose-reducing and lipid-regulating effectsis a compound with structures as shown in a formula I and a formula II and a pharmaceutically acceptable salt, wherein the structures as shown in the formula I and the formula II are specifically shown in the specification. The preparation is a tablet, a capsule, powder, a pill or an injection prepared by adding pharmaceutically acceptable auxiliary materials into the compound with the glucose-reducing and lipid-regulating effects. The application is the application of the compound with the glucose-reducing and lipid-regulating effects in preparing an FFA1/PPARdelta dual agonist. The application is the application of the compound with the glucose-reducing and lipid-regulating effects in preparation of drugs for preventing and/or treating glucose metabolic disorder and/or lipid metabolic disorder diseases. The compound and the medicinal salt thereof can be potentially used for treating or preventing diabetes, hyperlipidemia, fatty liver and other related metabolic syndromes, and have wide development prospects.

Biphenyl heterocyclic derivatives, their preparation and their use as medicaments (by machine translation)

The present invention relates to a novel biphenyl heterocyclic derivative represented by a general formula (I) and a preparation method thereof and use of a pharmaceutical composition containing the derivative for preparation of a drug for treating diabetes. The biphenyl heterocyclic derivative has extremely excellent hypoglycemic activity in vivo, and excellent in vivo safety and low liver toxicity risk of the compound having such a structure are unexpectedly found, and the novel biphenyl heterocyclic derivative may be used for preventing or treating diabetes.

Aromatic polycyclic carboxylic acid derivatives

The invention belongs to the field of medicine technology, and specifically relates to an aromatic polycyclic carboxylic acid derivative GPR40 receptor agonist with a general formula (I), a pharmaceutically acceptable salt thereof, and an ester or stereoi

Novel oxime ether derivative and preparation method thereof and application of derivative by serving as drug

The invention relates to a novel oxime ether derivative shown as a general formula (I) (please see the formula in the description) and a preparation method thereof and application of a pharmaceutical composition containing the derivative in preparation of a drug for treating diabetes and a metabolic syndrome. The oxime ether derivative has the excellent in-vivo hypoglycemic activity and can be used for preventing or treating the diabetes.

Novel nitrogen-containing heterocyclic derivative and preparation method thereof and application of derivative by serving as drug

The invention relates to a novel nitrogen-containing heterocyclic derivative shown as a general formula (I) (please see the formula in the description) and a preparation method thereof and application of a pharmaceutical composition containing the derivative in preparation of a drug for treating diabetes and a metabolic syndrome. The nitrogen-containing heterocyclic derivative has the excellent in-vivo hypoglycemic activity and can be used for preventing or treating the diabetes.

THIOARYL DERIVATIVES AS GPR120 AGONISTS

The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups (Het)Ar and R1 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups (Het)Ar and R1 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula (I), wherein the group (Het)Ar is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the group (Het)Ar is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.